ASMB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ASMB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The historical data trend for Assembly Biosciences's Cyclically Adjusted Price-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Assembly Biosciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Cyclically Adjusted Price-to-FCF | Get a 7-Day Free Trial | - | - | - | - | - |
Assembly Biosciences Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted Price-to-FCF | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Assembly Biosciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Assembly Biosciences's Cyclically Adjusted Price-to-FCF falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.
Assembly Biosciences's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, Assembly Biosciences's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | -3.352 | / | 131.7762 | * | 131.7762 | |
= | -3.352 |
Current CPI (Mar. 2024) = 131.7762.
Assembly Biosciences Quarterly Data
Free Cash Flow per Share | CPI | Adj_FreeCashFlowPerShare | |
201406 | -5.918 | 100.560 | -7.755 |
201409 | -5.642 | 100.428 | -7.403 |
201412 | -4.187 | 99.070 | -5.569 |
201503 | -3.979 | 99.621 | -5.263 |
201506 | -3.083 | 100.684 | -4.035 |
201509 | -3.616 | 100.392 | -4.746 |
201512 | -3.803 | 99.792 | -5.022 |
201603 | -6.420 | 100.470 | -8.420 |
201606 | -4.716 | 101.688 | -6.111 |
201609 | -5.503 | 101.861 | -7.119 |
201612 | -7.766 | 101.863 | -10.047 |
201703 | 24.284 | 102.862 | 31.110 |
201706 | -8.552 | 103.349 | -10.904 |
201709 | -7.573 | 104.136 | -9.583 |
201712 | -6.164 | 104.011 | -7.809 |
201803 | -9.216 | 105.290 | -11.534 |
201806 | -9.404 | 106.317 | -11.656 |
201809 | -8.066 | 106.507 | -9.980 |
201812 | -7.971 | 105.998 | -9.910 |
201903 | -11.887 | 107.251 | -14.605 |
201906 | -9.816 | 108.070 | -11.969 |
201909 | -8.613 | 108.329 | -10.477 |
201912 | -8.885 | 108.420 | -10.799 |
202003 | -8.650 | 108.902 | -10.467 |
202006 | -7.568 | 108.767 | -9.169 |
202009 | 3.598 | 109.815 | 4.318 |
202012 | -9.070 | 109.897 | -10.876 |
202103 | -11.014 | 111.754 | -12.987 |
202106 | -6.104 | 114.631 | -7.017 |
202109 | -4.973 | 115.734 | -5.662 |
202112 | -5.169 | 117.630 | -5.791 |
202203 | -6.858 | 121.301 | -7.450 |
202206 | -4.445 | 125.017 | -4.685 |
202209 | -4.910 | 125.227 | -5.167 |
202212 | -4.738 | 125.222 | -4.986 |
202303 | -5.511 | 127.348 | -5.703 |
202306 | -3.129 | 128.729 | -3.203 |
202309 | -3.162 | 129.860 | -3.209 |
202312 | 13.838 | 129.419 | 14.090 |
202403 | -3.352 | 131.776 | -3.352 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Assembly Biosciences (NAS:ASMB) Cyclically Adjusted Price-to-FCF Explanation
Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.
Thank you for viewing the detailed overview of Assembly Biosciences's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Alexander Schornstein | 10 percent owner | KAISER-FRIEDRICH-ALLEE 2, AACHEN 2M 52074 |
Nicole S White | officer: Chief Manufacturing Officer | C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD., FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Gilead Sciences Inc | 10 percent owner | 333 LAKESIDE DR, FOSTER CITY CA 94404 |
Jason A Okazaki | officer: Chief Legal & Business Officer | C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD, FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Delaney William E Iv | officer: CSO, Virology | C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD, FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Jeanette M Bjorkquist | officer: Principal Accounting Officer | C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD, FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080 |
John G Mchutchison | director, officer: CEO and President | 333 LAKESIDE DRIVE, FOSTER CITY X1 94404 |
Michael P. Samar | officer: See Remarks | C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN ST. SUITE 310, CARMEL IN 46032 |
Luisa M Stamm | officer: Chief Medical Officer | C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN ST, SUITE 310, CARMEL IN 46032 |
Michael Houghton | director | C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD., FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Lisa Johnson-pratt | director | C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122 |
Jacqueline Sybil Papkoff | officer: See remarks | C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN STREET, SUITE 310, CARMEL IN 46032 |
Gina Consylman | director | C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Richard James Colonno | officer: Chief Science Officer | ASSEMBLY BIOSCIENCES, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158 |
Thomas Joseph Russo | officer: CFO | C/O ASSEMBLY BIOSCIENCES, INC., 11711 N MERIDIAN ST, SUITE 310, CARMEL IN 46032 |
From GuruFocus
By PurpleRose PurpleRose • 07-11-2022
By PurpleRose PurpleRose • 07-20-2022
By Value_Insider Value_Insider • 12-19-2022
By sperokesalga sperokesalga • 02-15-2023
By Marketwired • 10-11-2023
By PurpleRose PurpleRose • 07-12-2022
By GuruFocusNews GuruFocusNews • 07-08-2022
By PurpleRose PurpleRose • 07-13-2022
By GuruFocusNews GuruFocusNews • 06-28-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.